HY3003
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- Hybio's HY3003 triple agonist gets FDA IND acceptance
Hybio Pharmaceutical said it received an FDA acceptance notice for its investigational new drug application for HY3003 injection; human trials can begin if the FDA does not impose a hold within 30 days. The candidate is a weekly subcutaneous GLP-1R/GIPR/GCGR triple-receptor agonist discovered using the company's AI peptide-chip screening technology, aimed at weight loss and type 2 diabetes. Hybio says preclinical work showed better weight reduction than the marketed dual agonist tirzepatide, a company-reported comparison.
36氪快讯 · 🔥 7
Experience and discussion from the community
Share my HY3003 experienceAsk about HY3003
Nobody has shared their experience with HY3003 yet.